146 related articles for article (PubMed ID: 8547668)
1. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
3. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a karyotypically normal cytotoxic leukemic T-cell line from a T-ALL sample engrafted in SCID mice.
Cesano A; O'Connor R; Nowell PC; Lange B; Clark SC; Santoli D
Blood; 1993 May; 81(10):2714-22. PubMed ID: 8490180
[TBL] [Abstract][Full Text] [Related]
5. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.
Cesano A; Visonneau S; Cioé L; Clark SC; Rovera G; Santoli D
J Clin Invest; 1994 Sep; 94(3):1076-84. PubMed ID: 8083348
[TBL] [Abstract][Full Text] [Related]
6. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
[TBL] [Abstract][Full Text] [Related]
7. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
9. An effective and safe marrow purging strategy using a lethally irradiated killer T cell clone.
Cesano A; Pierson G; Santoli D
Prog Clin Biol Res; 1994; 389():165-73. PubMed ID: 7700898
[No Abstract] [Full Text] [Related]
10. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
11. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
12. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
13. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
14. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi ML; Castelli C; Orazi A; Polli N; Bregni M; Siena S
Br J Haematol; 1991 Jun; 78(2):197-205. PubMed ID: 2064957
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Ramsay NK
Blood; 1992 Feb; 79(4):1094-104. PubMed ID: 1531306
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model.
Gravatt LC; Chaffee S; Hebert ME; Halperin EC; Friedman HS; Kurtzberg J
Leukemia; 1993 Aug; 7(8):1261-7. PubMed ID: 8350627
[TBL] [Abstract][Full Text] [Related]
17. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
18. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade.
Koh CY; Ortaldo JR; Blazar BR; Bennett M; Murphy WJ
Blood; 2003 Dec; 102(12):4067-75. PubMed ID: 12893752
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
20. Synergistic and antagonistic effects of IL-1 alpha and IL-4, respectively, on the IL-2-dependent growth of a T cell receptor-gamma delta+ human T leukemia cell line.
Santoli D; O'Connor R; Cesano A; Phillips P; Colt TL; Lange B; Clark SC; Rovera G
J Immunol; 1990 Jun; 144(12):4703-11. PubMed ID: 2351825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
